San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

The invention relates to compositions and methods for gene expression analysis. In some embodiments, the invention provides compositions and methods for amplifying targets in a degraded nucleic acid sample. In some embodiments, the invention provides methods for determining the quality of nucleic acids (e.g., the degree of degradation) in a nucleic acid sample. The invention also provides methods for producing a gene expression profile from a degraded RNA sample.


Patent
AltheaDx | Date: 2013-09-11

The invention relates to compositions and methods for the analysis of biomolecules associated with cells, where the presence or absence of a particular biomolecule (e.g. an expressed protein or a nucleic acid gene expression product) associated with the cells is examined. The invention provides methods for single cell biochemical analysis, as well as instrumentation for the single-cell biochemical analysis. Most advantageously, the invention affords methods and instrumentation for high-throughput biochemical analysis of large numbers of single cells.


Patent
AltheaDx | Date: 2015-04-20

This invention provides methods, compositions and kits for gene expression analysis and gene expression profiling. The methods of the invention are highly sensitive; have a wide dynamic range; are rapid and inexpensive; have a high throughput; and allow the simultaneous differential analysis of a defined set of genes. The methods, compositions and kits of the invention also provide tools for gene expression data collection and relational data analysis.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cvlzkw/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2015 to 2019" report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Report Buyers have access to Price and Volume Data for the following individual tests:


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vx3f8n/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 - Global Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 10. The Future of the Clinical Laboratory


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vx3f8n/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 - Global Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 10. The Future of the Clinical Laboratory


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2jd9w8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ws2hdw/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - North American Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 7. The Future of the Clinical Laboratory


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ws2hdw/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - North American Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. 7. The Future of the Clinical Laboratory


News Article | March 9, 2015
Site: www.socaltech.com

San Diego-based molecular diagnostics developer AltheaDX has dropped its plans for an IPO, saying in a SEC filing Monday that it is withdrawing its S-1 and does not plan to pursue its IPO. AltheaDx--which originally filed confidentially for an IPO in July of 2014, and revealed its plans in December, said in its filing that the terms on the public marketplace are "not sufficiently attractive" to the company. AltheaDx had originally planned to IPO on the NASDAQ Global Market as IDGX. The company is venture backed by Telegraph Hill Partners and Alma Life Sciences.

Loading AltheaDx collaborators
Loading AltheaDx collaborators